Neurologic Imaging

Should You Order Ultrasound First for Thyrotoxicosis? An ACR-Guided Workflow

·
Should You Order Ultrasound First for Thyrotoxicosis? An ACR-Guided Workflow

A 45-year-old woman presents to her primary care physician with a three-month history of anxiety, palpitations, weight loss despite an increased appetite, and heat intolerance. Her heart rate is 110 bpm, and a fine tremor is noted in her hands. Laboratory work confirms a suppressed Thyroid-Stimulating Hormone (TSH) and an elevated free T4, confirming thyrotoxicosis. The immediate clinical question is to determine the underlying cause to guide treatment. What is the most appropriate initial imaging study to order? This article details the American College of Radiology (ACR) Appropriateness Criteria for this exact scenario, where a Thyroid Ultrasound is rated as ‘Usually Appropriate’ and serves as the foundational first step.

Who Fits This Clinical Scenario?

This workflow applies specifically to patients with newly diagnosed, biochemically confirmed thyrotoxicosis requiring initial etiologic evaluation. The key inclusion criteria are suppressed TSH levels with or without elevated free T4 or T3 levels, coupled with clinical signs and symptoms of hyperthyroidism. The goal of initial imaging in this context is to differentiate the primary causes of excess thyroid hormone production or release.

This guidance is distinct from other common thyroid-related presentations. This article does not apply if your patient presents with:

  • A palpable thyroid nodule but is euthyroid. A patient with a neck lump and normal thyroid function tests follows a different diagnostic pathway focused on nodule risk stratification.
  • Primary hypothyroidism. A patient with an elevated TSH and low free T4 levels rarely requires initial imaging, as the diagnosis is typically autoimmune (Hashimoto’s thyroiditis) and managed medically.
  • A suspected goiter without thyrotoxicosis. The workup for an enlarged thyroid gland in a euthyroid patient focuses on compressive symptoms and nodule evaluation, which is a separate clinical question.

Applying this workflow to the correct patient—one with confirmed thyrotoxicosis—is critical for efficient and accurate diagnosis.

What Diagnoses Are You Working Up in This Scenario?

When a patient has thyrotoxicosis, imaging helps distinguish between several potential underlying causes. The initial imaging choice is designed to provide anatomical information that, when combined with clinical and serological data, points toward a specific diagnosis.

Graves’ Disease: This is the most common cause of true hyperthyroidism. It is an autoimmune disorder where antibodies stimulate the TSH receptor, leading to diffuse overproduction of thyroid hormone. Imaging is used to look for characteristic features like diffuse gland enlargement, hypoechogenicity, and markedly increased blood flow.

Toxic Multinodular Goiter (TMNG) or Toxic Adenoma: In these conditions, one or more thyroid nodules develop autonomy and produce thyroid hormone independent of TSH stimulation. TMNG involves multiple nodules, while a toxic adenoma (or Plummer’s disease) involves a single nodule. Imaging is essential to identify, count, and measure these nodules.

Thyroiditis: Conditions like subacute (de Quervain’s) thyroiditis or postpartum thyroiditis involve inflammation and destruction of thyroid follicles, causing a temporary release of pre-formed hormone. This is thyrotoxicosis without true hyperthyroidism (i.e., no new hormone synthesis). Imaging can reveal signs of inflammation and reduced vascularity, which helps differentiate it from Graves’ disease.

Less Common Causes: While less frequent, imaging can also provide clues for other etiologies, such as a struma ovarii (an ovarian teratoma containing thyroid tissue) or metastatic thyroid cancer, though these are not the primary targets of the initial workup.

Why Is Thyroid Ultrasound the Recommended Initial Study?

For the initial evaluation of thyrotoxicosis, the ACR designates US thyroid as ‘Usually appropriate’. This recommendation is based on its high diagnostic utility, safety profile, and ability to guide subsequent steps. Ultrasound provides a detailed anatomical assessment of the thyroid gland that is crucial for differentiating the most common causes of thyrotoxicosis.

Ultrasound excels at identifying features suggestive of Graves’ disease, such as diffuse hypoechogenicity and hyperemia (the “thyroid inferno” on color Doppler). It is also the most sensitive modality for detecting and characterizing nodules, which is critical for diagnosing a toxic adenoma or toxic multinodular goiter. In cases of thyroiditis, ultrasound may demonstrate ill-defined hypoechoic areas and decreased vascularity, consistent with inflammation rather than overproduction.

A key advantage of ultrasound is its complete lack of ionizing radiation (0 mSv), making it safe for all patients, including younger individuals and those who are pregnant. It does not require IV contrast and is widely available and relatively inexpensive.

Why are other studies rated lower for initial imaging?

  • Nuclear Medicine Scans: While an I-123 uptake scan is also ‘Usually appropriate’, it is often considered a complementary or second-line study. It assesses gland function (showing diffuse high uptake in Graves’, focal “hot” spots in toxic adenoma/TMNG, and low uptake in thyroiditis) rather than anatomy. Ultrasound is often performed first to provide the anatomical context.
  • CT and MRI of the Neck: These modalities are ‘Usually not appropriate’ for the initial workup. CT neck with IV contrast (☢☢☢ 1-10 mSv) exposes the patient to ionizing radiation and, more importantly, the iodinated contrast load can interfere with subsequent radioactive iodine uptake scans or therapy for weeks to months. MRI offers excellent soft tissue detail but provides limited functional information about the thyroid and is not superior to ultrasound for the primary diagnostic questions in thyrotoxicosis.

The initial choice of ultrasound provides a safe, effective anatomical roadmap. Once you’ve decided on this study, our protocol guide covers the technique and reading principles in detail: US Thyroid.

What’s Next After Thyroid Ultrasound? Downstream Workflow

The results of the thyroid ultrasound guide the next steps in the diagnostic and management pathway, often in conjunction with thyroid receptor antibody (TRAb) testing.

  • If the US shows diffuse hypoechogenicity and hypervascularity: This is highly suggestive of Graves’ disease. The diagnosis can often be confirmed with a positive TRAb test, potentially avoiding the need for a nuclear medicine scan. Treatment typically involves antithyroid medications, radioactive iodine ablation, or surgery.
  • If the US identifies one or more distinct nodules (≥1 cm): This raises suspicion for a toxic adenoma or toxic multinodular goiter. The next step is almost always a radioactive iodine uptake and scan (RAIUS). This functional study will determine if the nodules are “hot” (autonomously functioning) and confirm the diagnosis.
  • If the US shows features of thyroiditis (e.g., heterogeneous echotexture, decreased vascularity, gland tenderness): This finding, especially with a history of recent viral illness or pregnancy and elevated inflammatory markers, points toward a destructive thyroiditis. A RAIUS would show near-absent uptake, confirming the diagnosis. Management is typically supportive with beta-blockers and anti-inflammatory agents.
  • If the US is normal: A structurally normal gland in a thyrotoxic patient may still be consistent with early Graves’ disease. Correlating with TRAb levels is key. If TRAb is negative, a RAIUS is necessary to assess for other causes.

The ultrasound is rarely the final step, but it is the critical decision point that directs the subsequent, more specific functional testing.

Pitfalls to Avoid (and When to Get Help)

Navigating the workup for thyrotoxicosis requires careful integration of clinical, lab, and imaging data. Here are a few common pitfalls to avoid:

  • Ordering CT with contrast first: This is the most significant pitfall. The iodine load from CT contrast will “stun” the thyroid, rendering a subsequent radioactive iodine scan useless for up to 2-3 months. Always start with ultrasound.
  • Ignoring clinical context: An ultrasound showing a hypoechoic gland could be Graves’ disease or thyroiditis. The clinical picture—neck pain, recent pregnancy, duration of symptoms—is essential for correct interpretation.
  • Over-reliance on Doppler alone: While a “thyroid inferno” is classic for Graves’, its absence does not rule it out. Similarly, vascularity can be variable in nodules. Correlate with all other findings.
  • Failing to order a RAIUS for nodular disease: Ultrasound cannot determine if a nodule is functional (“hot”) or not (“cold”). This distinction is critical for management and requires a nuclear medicine scan.

If the clinical picture and imaging findings are discordant, or if the diagnosis remains unclear after initial studies, consultation with an endocrinologist is the appropriate next step.

Related ACR Topics and Tools

This article provides a deep dive into one specific clinical scenario. For a broader view of imaging across all common thyroid-related presentations, from nodules to cancer surveillance, please see our comprehensive parent guide. For other tools to help with ordering decisions, see the resources below.

Frequently Asked Questions

Why not just order a radioactive iodine uptake scan (RAIUS) first for thyrotoxicosis?

While a RAIUS is also rated ‘Usually Appropriate’ and provides crucial functional data, a thyroid ultrasound is often preferred as the initial step because it provides essential anatomical information. Ultrasound can identify non-functioning nodules that may require separate evaluation (e.g., for malignancy risk) which a RAIUS would miss. Many clinicians order the ultrasound first to get a structural map, which then helps interpret the subsequent functional RAIUS.

Is a thyroid ultrasound necessary if my patient has classic signs of Graves’ disease and a positive TRAb test?

In a patient with overt clinical and biochemical thyrotoxicosis and a strongly positive TSH-receptor antibody (TRAb) test, the diagnosis of Graves’ disease is highly certain. Some guidelines suggest that imaging may not be necessary in this specific context. However, many endocrinologists still obtain a baseline ultrasound to assess for concomitant nodules, which are present in a significant minority of patients with Graves’ disease and may require separate management.

What if the thyrotoxicosis is very mild or subclinical?

The imaging workup is generally the same. The goal remains to determine the etiology. An ultrasound is still the recommended first step to assess for structural abnormalities like nodules or signs of autoimmune disease, which is just as important in subclinical thyrotoxicosis as it is in overt disease.

Can I use CT or MRI if I’m also concerned about a neck mass or compressive symptoms?

If there is a strong clinical suspicion for an invasive process, substernal goiter with significant compression, or another primary neck pathology unrelated to thyrotoxicosis, then CT or MRI may be warranted. However, for the initial workup of thyrotoxicosis itself, these are ‘Usually not appropriate’. If you must order a CT, a non-contrast study is preferred to avoid iodine contamination that would preclude a future RAIU scan.

Does pregnancy change the initial imaging recommendation for thyrotoxicosis?

Yes, significantly. Thyroid ultrasound is the only appropriate imaging modality for thyrotoxicosis during pregnancy as it involves no ionizing radiation. All nuclear medicine studies (I-123, I-131, Tc-99m) are absolutely contraindicated in pregnancy due to fetal radiation exposure. The workup in pregnant patients relies heavily on clinical findings, serial lab tests, and ultrasound.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 29, 2026